SIC
CTKB icon

SJS Investment Consulting’s Cytek Biosciences CTKB Stock Holding History

SJS Investment Consulting’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$27 – 2903
2026
Q1 		$27 Buy
+6
New +$28 ﹤0.01% 2344

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

SJS Investment Consulting's CTKB Position: Q2 2026 in Review

SJS Investment Consulting sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 6 shares — an estimated $27 sold.

SJS Investment Consulting first reported a position in CTKB in Q1 2026 and held it in 1 quarter. The position peaked at $27 in Q1 2026. 63 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • SJS Investment Consulting reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 6 Cytek Biosciences shares in Q2 2026, an estimated $27.
  • SJS Investment Consulting first reported a position in Cytek Biosciences in Q1 2026 and held it in 1 quarter.
  • SJS Investment Consulting's Cytek Biosciences position peaked at $27 in Q1 2026.
  • 63 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.